fluoxetine has been researched along with Briquet Syndrome in 29 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)." | 7.72 | Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Sklarsky, KG; Summergrad, P, 2004) |
| "The recent clinical studies on hypericum extract support the present indications for its use in mild to moderate depression and depressive episodes." | 4.84 | [New developments in hypericum extracts: data on efficacy and interactions]. ( Kraft, K, 2007) |
| "In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)." | 3.72 | Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Sklarsky, KG; Summergrad, P, 2004) |
| "The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg)." | 3.72 | Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. ( Alpert, JE; Fava, M; Hughes, ME; Nierenberg, AA; Papakostas, GI; Petersen, T, 2004) |
| "One hundred and three patients of major depressive disorders were observed." | 2.79 | Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period. ( Gu, S; Guo, J; Luo, H; Qu, W; Tang, Q, 2014) |
| "Patients suffering from major depressive disorder (MDD) have been reported to have substantial long-lasting limitations in multiple domains of health-related quality of life (HRQoL)." | 2.78 | Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. ( Cao, Y; Li, W; Luo, X; Malison, RT; Shen, J; Zhang, Y, 2013) |
| "Fluoxetine has a better analgesic effect than a placebo in treating persistent somatoform pain disorder, and is considered a safe treatment; its analgesic effect may be related to an antidepressant effect." | 2.74 | A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. ( Li, CB; Li, QW; Lu, Z; Luo, YL; Wu, WY; Zhang, MY, 2009) |
| "Pimozide was not more effective than placebo: two (18." | 2.71 | Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. ( Phillips, KA, 2005) |
| "Fluoxetine was generally well tolerated." | 2.70 | A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. ( Albertini, RS; Phillips, KA; Rasmussen, SA, 2002) |
| "Major depressive disorder is a medical condition that includes abnormalities of affect and mood, cognition, and physical functioning." | 2.42 | The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. ( Fava, M, 2003) |
| "This case report describes numbness and dysmorphic symptoms in the upper facial area associated with fluoxetine." | 1.32 | Serotonin reuptake inhibitor induced sensory disturbances. ( Praharaj, SK, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 7 (24.14) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Subramanian, K | 1 |
| Manohar, H | 1 |
| Menon, V | 1 |
| Cao, Y | 1 |
| Li, W | 1 |
| Shen, J | 1 |
| Malison, RT | 1 |
| Zhang, Y | 1 |
| Luo, X | 1 |
| Qu, W | 1 |
| Gu, S | 1 |
| Luo, H | 1 |
| Tang, Q | 1 |
| Guo, J | 1 |
| Papakostas, GI | 3 |
| McGrath, P | 1 |
| Stewart, J | 1 |
| Charles, D | 1 |
| Chen, Y | 1 |
| Mischoulon, D | 2 |
| Dording, C | 1 |
| Fava, M | 5 |
| Phillips, KA | 5 |
| Kelly, MM | 1 |
| Ipser, JC | 1 |
| Sander, C | 1 |
| Stein, DJ | 1 |
| Kendrick, T | 1 |
| Chatwin, J | 1 |
| Dowrick, C | 1 |
| Tylee, A | 1 |
| Morriss, R | 1 |
| Peveler, R | 1 |
| Leese, M | 1 |
| McCrone, P | 1 |
| Harris, T | 1 |
| Moore, M | 1 |
| Byng, R | 1 |
| Brown, G | 1 |
| Barthel, S | 1 |
| Mander, H | 1 |
| Ring, A | 1 |
| Kelly, V | 1 |
| Wallace, V | 1 |
| Gabbay, M | 1 |
| Craig, T | 1 |
| Mann, A | 1 |
| Luo, YL | 1 |
| Zhang, MY | 1 |
| Wu, WY | 1 |
| Li, CB | 1 |
| Lu, Z | 1 |
| Li, QW | 1 |
| Kushwaha, V | 1 |
| Chadda, RK | 1 |
| Mehta, M | 1 |
| al-Adawi, S | 1 |
| Martin, R | 1 |
| al-Naamani, A | 1 |
| Obeid, Y | 1 |
| al-Hussaini, A | 1 |
| Petersen, TJ | 1 |
| Iosifescu, DV | 1 |
| Summergrad, P | 1 |
| Sklarsky, KG | 1 |
| Alpert, JE | 3 |
| Nierenberg, AA | 2 |
| Petersen, T | 1 |
| Hughes, ME | 1 |
| Greco, T | 1 |
| Eckert, G | 1 |
| Kroenke, K | 1 |
| Praharaj, SK | 1 |
| Farabaugh, A | 1 |
| Wu, SL | 1 |
| Mascarini, A | 1 |
| Tossani, E | 1 |
| Kraft, K | 1 |
| Han, C | 1 |
| Pae, CU | 1 |
| Lee, BH | 1 |
| Ko, YH | 1 |
| Masand, PS | 1 |
| Patkar, AA | 1 |
| Jung, IK | 1 |
| Atala, KD | 1 |
| Albertini, RS | 2 |
| Brandenburg, S | 1 |
| Tuynman-Qua, H | 1 |
| Verheij, R | 1 |
| Pepplinkhuizen, L | 1 |
| Small, GW | 1 |
| Hamilton, SH | 1 |
| Bystritsky, A | 1 |
| Meyers, BS | 1 |
| Nemeroff, CB | 1 |
| Cleare, AJ | 1 |
| Wessely, SC | 1 |
| Symonds, A | 1 |
| Ferrando, SJ | 1 |
| Goldman, JD | 1 |
| Charness, WE | 1 |
| Dominguez, RA | 1 |
| Puig, A | 1 |
| Rasmussen, SA | 1 |
| Hollander, E | 1 |
| Liebowitz, MR | 1 |
| Winchel, R | 1 |
| Klumker, A | 1 |
| Klein, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529] | Phase 4 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Silymarin Treatment of Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Study[NCT02843451] | Phase 2 | 0 participants (Actual) | Interventional | 2016-10-31 | Withdrawn (stopped due to Focus on other studies) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluoxetine and Briquet Syndrome
| Article | Year |
|---|---|
Pharmacotherapy and psychotherapy for body dysmorphic disorder.
Topics: Adrenergic Uptake Inhibitors; Body Image; Clomipramine; Cognitive Behavioral Therapy; Desipramine; F | 2009 |
The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Norepi | 2003 |
[New developments in hypericum extracts: data on efficacy and interactions].
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bridg | 2007 |
Treatment of body-dysmorphic disorder with serotonin reuptake blockers.
Topics: Adult; Body Image; Clomipramine; Diagnosis, Differential; Female; Fluoxetine; Humans; Male; Middle A | 1989 |
15 trials available for fluoxetine and Briquet Syndrome
| Article | Year |
|---|---|
Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Asian People; China; Depressive Disorder, M | 2013 |
Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
Topics: Adult; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Combinations; | 2014 |
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depress | 2008 |
Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder.
Topics: Double-Blind Method; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Soma | 2009 |
Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care
Topics: Adolescent; Adult; Aged; Comorbidity; Cost-Benefit Analysis; Depression; Female; Fluoxetine; Humans; | 2009 |
A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents, Second-Generation; Depression; Double-Bl | 2009 |
Psychotherapeutic intervention in somatisation disorder: results of a controlled study from India.
Topics: Adult; Breathing Exercises; Combined Modality Therapy; Female; Fluoxetine; Humans; India; Male; Prob | 2013 |
The outcome of physical symptoms with treatment of depression.
Topics: Depressive Disorder; Female; Fluoxetine; Follow-Up Studies; Health Status; Health Surveys; Humans; M | 2004 |
Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
Topics: Adult; Antipsychotic Agents; Delusions; Double-Blind Method; Drug Therapy, Combination; Female; Fluo | 2005 |
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety; D | 2005 |
Olanzapine augmentation of fluoxetine in body dysmorphic disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; Female | 2005 |
Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Health St | 2008 |
Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fl | 1995 |
Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms.
Topics: 1-Naphthylamine; Acquired Immunodeficiency Syndrome; Adaptation, Psychological; Adult; Depressive Di | 1997 |
A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Topics: Adult; Double-Blind Method; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Sele | 2002 |
10 other studies available for fluoxetine and Briquet Syndrome
| Article | Year |
|---|---|
Family accommodation in somatoform disorders-its effects on diagnosis and management: A case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Caregivers; Diagnosis, Differen | 2017 |
Body dysmorphic disorder in Oman: cultural and neuropsychological findings.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Image; Cultural Characteristics; Diagnosis, Di | 2001 |
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
Topics: Adult; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Humans; Male; Personality Inventory | 2004 |
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Prospective Studies; S | 2004 |
Serotonin reuptake inhibitor induced sensory disturbances.
Topics: Adult; Fluoxetine; Humans; Hypesthesia; Male; Selective Serotonin Reuptake Inhibitors; Somatoform Di | 2004 |
Case study: body dysmorphic disorder in adolescents.
Topics: Adolescent; Body Image; Depressive Disorder; Female; Fluoxetine; Humans; Male; Phobic Disorders; Psy | 1995 |
Treatment of premenstrual syndrome with fluoxetine: an open study.
Topics: Adult; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Personality Inventory; Pr | 1993 |
Fluoxetine and chronic fatigue syndrome.
Topics: Antidepressive Agents, Second-Generation; Fatigue Syndrome, Chronic; Fluoxetine; Humans; Somatoform | 1996 |
The mind and the butt.
Topics: Adult; Buttocks; Combined Modality Therapy; Depression, Postpartum; Female; Fluoxetine; Humans; Obse | 1996 |
Olfactory reference syndrome responds to clomipramine but not fluoxetine: a case report.
Topics: Adult; Clomipramine; Comorbidity; Delusions; Depressive Disorder; Fluoxetine; Humans; Male; Obsessiv | 1997 |